AbbVie Digital Transformation Strategy Report 2024 - Technology Focus, Technology Initiatives, ICT Budget and Contracts

Group 1 - The report titled "Enterprise Tech Ecosystem Series: AbbVie Inc. - 2024" provides insights into AbbVie's technology activities, including digital transformation strategies and innovation programs [1][2] - AbbVie is a diversified research-based biopharmaceutical company focused on developing, manufacturing, marketing, and selling medicines for serious and complex diseases [3] - The company's product portfolio includes immunology, oncology, aesthetics, neuroscience, and eye care products [3][4] Group 2 - AbbVie's immunology products include Humira, Skyrizi, and Rinvoq, while its oncology products feature Imbruvica, Venclexta, Epkinly, and Elahere [4] - The aesthetics product portfolio consists of Botox Cosmetic, the Juvederm Collection of Fillers, Alloderm regenerative dermal tissue, and Latisse eyelash solution [4] - AbbVie also manufactures medicines for hepatitis C virus infection, metabolic and hormonal diseases, and endocrinology diseases [5] Group 3 - The report outlines key topics such as digital transformation strategy, innovation programs, technology initiatives, partnerships, ICT budget, and major contracts [5] - Insights into AbbVie's technology themes, objectives, and benefits of various initiatives are included [2][5] - The report aims to provide a comprehensive understanding of AbbVie's tech operations and strategies [5]